Carmel Capital Partners LLC Sells 4,835 Shares of IQVIA Holdings Inc. $IQV

Carmel Capital Partners LLC trimmed its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 32.5% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,043 shares of the medical research company’s stock after selling 4,835 shares during the period. IQVIA accounts for approximately 0.8% of Carmel Capital Partners LLC’s holdings, making the stock its 27th largest holding. Carmel Capital Partners LLC’s holdings in IQVIA were worth $1,908,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Verdence Capital Advisors LLC bought a new position in shares of IQVIA in the second quarter worth about $3,612,000. Amundi raised its position in IQVIA by 46.3% in the 2nd quarter. Amundi now owns 1,279,817 shares of the medical research company’s stock worth $210,722,000 after purchasing an additional 405,250 shares during the last quarter. Diversified Trust Co lifted its holdings in IQVIA by 57.2% during the 3rd quarter. Diversified Trust Co now owns 42,579 shares of the medical research company’s stock worth $8,087,000 after buying an additional 15,487 shares in the last quarter. Act Two Investors LLC bought a new position in IQVIA in the 2nd quarter valued at $26,528,000. Finally, Oregon Public Employees Retirement Fund increased its stake in shares of IQVIA by 37.1% in the 3rd quarter. Oregon Public Employees Retirement Fund now owns 19,463 shares of the medical research company’s stock valued at $3,697,000 after buying an additional 5,271 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Down 0.9%

Shares of NYSE IQV opened at $239.15 on Friday. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $247.04. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.70 and a current ratio of 0.70. The stock has a market cap of $40.73 billion, a P/E ratio of 32.81, a P/E/G ratio of 2.46 and a beta of 1.36. The firm has a 50 day moving average price of $228.82 and a 200 day moving average price of $205.11.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The company had revenue of $4.10 billion for the quarter, compared to analysts’ expectations of $4.07 billion. During the same period last year, the firm posted $2.84 earnings per share. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Insider Activity at IQVIA

In other news, insider Eric Sherbet sold 4,000 shares of IQVIA stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total transaction of $878,800.00. Following the transaction, the insider owned 27,108 shares in the company, valued at $5,955,627.60. The trade was a 12.86% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.60% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Wall Street Zen cut IQVIA from a “buy” rating to a “hold” rating in a report on Saturday, January 17th. Evercore ISI raised their target price on shares of IQVIA from $220.00 to $240.00 and gave the company an “outperform” rating in a research note on Wednesday, October 8th. Mizuho set a $266.00 price target on shares of IQVIA in a research note on Friday, January 9th. BMO Capital Markets initiated coverage on shares of IQVIA in a research note on Thursday, November 13th. They issued an “outperform” rating and a $260.00 price objective on the stock. Finally, TD Cowen lifted their target price on shares of IQVIA from $215.00 to $245.00 and gave the stock a “hold” rating in a report on Thursday. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, IQVIA presently has an average rating of “Moderate Buy” and an average price target of $251.06.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.